Aktis Oncology (AKTS) director Form 3 shows stock option grants

Rhea-AI Filing Summary

Aktis Oncology director Ken Herrmann filed an initial Form 3 reporting his beneficial ownership in the company mainly through stock options to buy common stock.

The filing lists six stock option grants with exercise prices from $0.08 to $18.00 per share and expiration dates between November 23, 2030 and January 7, 2036. Options covering 6,571 and 19,714 shares have vested in full, while other grants, including 26,285, 64,399 and 10,514 underlying shares, vest in monthly installments tied to his continuous service. A grant covering 18,933 shares is scheduled to vest in full on January 8, 2027. All reported options are held directly.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Herrmann Ken

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 6,571 shares (Direct)

Footnotes (1)

1. These options have vested in full. These options have vested in full. 25% of the original number of shares subject to the option vested on November 1, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. Beginning on May 13, 2024, 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments, subject to the Reporting Person's continuous service through each vesting date, inclusive. Beginning on October 9, 2024, 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments, subject to the Reporting Person's continuous service through each vesting date, inclusive. The number of shares subject to the option shall vest in full on January 8, 2027, subject to the Reporting Person's continuous service through such vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Herrmann Ken

(Last) (First) (Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026

3. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	11/23/2030	Common Stock	6,571	$0.08	D
Stock Option (Right to Buy)	(2)	04/14/2031	Common Stock	19,714	$1.91	D
Stock Option (Right to Buy)	(3)	11/15/2032	Common Stock	26,285	$3.66	D
Stock Option (Right to Buy)	(4)	06/30/2034	Common Stock	64,399	$4.95	D
Stock Option (Right to Buy)	(5)	12/09/2034	Common Stock	10,514	$10.66	D
Stock Option (Right to Buy)	(6)	01/07/2036	Common Stock	18,933	$18	D

Explanation of Responses:

1. These options have vested in full.

2. These options have vested in full.

3. 25% of the original number of shares subject to the option vested on November 1, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

4. Beginning on May 13, 2024, 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments, subject to the Reporting Person's continuous service through each vesting date, inclusive.

5. Beginning on October 9, 2024, 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments, subject to the Reporting Person's continuous service through each vesting date, inclusive.

6. The number of shares subject to the option shall vest in full on January 8, 2027, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ken Herrmann	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.